Cormorant Asset Management is a Boston-based investment manager with investment focus in both public and private market innovative companies in the biotechnology and life sciences marketplace.
Massachusetts, United States
|2018-04-26||Innovent Biologics||Series E||$150M||Ally Bridge Group, Capital Group Private Markets, Hillhouse Capital Management, Legend Capital, Lilly Asia Ventures, Rock Springs Capital, Taikang Life Insurance Company, and Temasek Holdings|
|2018-04-25||Corvidia Therapeutics||Series B||$60M||Andera Partners, Apple Tree Partners, Fresenius Medical Care, HBM Healthcare Investments, MedImmune Ventures, Sofinnova Partners, and Venrock|
|2018-04-06||Constellation Pharmaceuticals||Series D||$100M||Casdin Capital, Deerfield Management, Fidelity Investments, Hillhouse Capital Management, NS Investment, OrbiMed Advisors, Sirona Capital, SR One, The Column Group, Third Rock Ventures, Topspin Partners, University Of California, and Venrock|
|2018-04-05||Eidos Therapeutics||Series B||$64M||Aisling Capital, Amzak Capital Management, BridgeBio Pharma, Janus Henderson Global Investors, Perceptive Advisors, RA Capital Management, and Viking Global Investors|
|2018-04-02||CMAB Biopharma||Series B||$34M||C-Bridge Capital, CDBI Partners, Hangzhou Tigermed Consulting, and Qianhai Fund of Funds|